An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

AbbVie

Status and phase: Active, not recruiting; Phase 3

Conditions: Multiple Myeloma; Non-Hodgkin's Lymphoma; Cancer; Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia

Treatments: Drug: Venetoclax

Study type: Interventional

Funder types: Industry

Identifiers

NCT03844048

M19-388

2022-501522-38-00 (Other Identifier)

Details and patient eligibility

About

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

Enrollment: 165 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
• Male subject agrees to refrain from sperm donation.
• Female subjects must not be pregnant or breastfeeding.

Exclusion criteria

• None.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

165 participants in 1 patient group

Venetoclax

Experimental group

Description:

Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled.

Treatment:

Drug: Venetoclax